Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment
Ipsen · Early-stage Breast Cancer
Not applicable
Completed
450
2026-07
Industry sponsor intelligence
IpsenClinical Pipeline.
Lead-sponsor view of Ipsen's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 42
- Recruiting
- 0
- Active
- 0
- Completed
- 31
- Results posted
- 19
- Avg enrollment
- 68
Pipeline overview
Programs by phase and activity.
Velocity
Ipsen trials by start year
Study start year · indexed snapshot
Development
Trials by phase
31phase labels
Early Phase 10
Phase 11
Phase 29
Phase 316
Phase 45
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Lanreotide → | 38 | 1 | 9 | 14 | 4 | 0 |
| Triptorelin → | 4 | 0 | 0 | 2 | 1 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
Ipsen · Advanced Prostate Cancer · Metastatic Prostate Cancer
Phase 3
Completed
195
2025-09
Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate
Ipsen · Prostate Cancer
Phase 3
Completed
147
2025-07
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
Ipsen · Endocrine Tumors
Phase 3
Completed
264
2025-03
Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China
Ipsen · Acromegaly
Not applicable
Completed
129
2025-01
United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting
Ipsen · Neuroendocrine Tumours (NET)
Not applicable
Completed
80
2024-12
Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
Ipsen · Gastroenteropancreatic Neuroendocrine Tumor
Phase 3
Completed
43
2024-10
Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
Ipsen · Acromegaly
Phase 3
Completed
108
2022-10
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
Ipsen · Carcinoid Syndrome
Phase 3
Completed
115
2022-10
Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour
Ipsen · Non Functioning Entero-pancreatic Endocrine Tumour
Phase 3
Completed
89
2022-10
Showing 10 of 31 studies
Search sponsor records
All Ipsen studies.
This page groups studies where Ipsen is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
42 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT05377684Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer TreatmentJul 10, 2026NCT05590793Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the ProstateSep 9, 2025NCT05458856Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the ProstateJul 25, 2025NCT01673984GP Extended Action TriptorelinMay 23, 2025NCT00353496Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine TumoursMar 5, 2025NCT05431803Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in ChinaJan 31, 2025NCT04649580United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration SettingDec 17, 2024NCT04852679Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETsOct 1, 2024NCT05922579A Study to Collect the Somatuline® Injector Device Preferences of Patients Living With Neuroendocrine Tumor (NET) and Nurses Involved in the Care of Patients With NETFeb 29, 2024NCT00690898Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland MacroadenomaOct 14, 2022